CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? .......... 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW
PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic .......... 562
D.A. Fruman and C. Rommel

RESEARCH BRIEFS
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence .......... 573

Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs .......... 580

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.

IN THIS ISSUE
Highlighted research articles ........................................ vi

NEWS IN BRIEF
Important news stories affecting the community ................. 541

Q&A: William Sellers on Success in Small Molecules .......... 543

Upcoming Battles in the War on Cancer ...................... 544

NEWS IN DEPTH

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature .............. 547

ONLINE
For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews.

VIEWS
In The Spotlight

Anti-MET Targeted Therapy Has Come of Age: The First Durable Complete Response with MetMAb in Metastatic Gastric Cancer .......... 550
Y. Feng and P.C. Ma
Commentary on Catenacci et al., p. 573

Genomic Investigation of Dedifferentiated Liposarcoma Suggests a Role for Therapeutic Targeting of the Tumor Epigenome .......... 555
P.S. Meltzer and L.J. Heilman
Commentary on Taylor et al., p. 587

A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non–Small Cell Lung Cancer .......... 557
M. Rodriguez-Paredes and M. Esteller
Commentary on Juergens et al., p. 598

CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? .......... 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW
PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic .......... 562
D.A. Fruman and C. Rommel

RESEARCH BRIEFS
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence .......... 573

Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs .......... 580

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.
IntRODUCTION

A 48-year-old woman with a remote history of stage I, right-erosive epirubicin (MAGIC regimen, i.e., epirubicin, cisplatin, previously exposure to anthracyclines, she did not receive periop-

Methods

The final pathology report was pT3, N1, M1 metastatic disease. The primary tumor enectomy and cholecystectomy in April 2007. The primary tumor

Results

The complete response lasted 2 years; the cancer recurred as a peritoneal deposit invading into the liver and retroperitoneal lymph nodes. The patient was treated with systemic chemotherapy, including docetaxel and cisplatin, but disease progressed despite treatment.

Discussion

The case report highlights the potential role of anti-Met therapy in the management of advanced gastric cancer. Anti-Met therapy may offer a targeted approach for patients with specific molecular alterations, warranting further investigation in clinical trials.

ACKNOWLEDGMENTS

The authors thank the patient and her family for their trust and cooperation. They also acknowledge the contributions of the medical and surgical teams at the hospital where the patient was treated.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.